About this Research Topic
The tissue-restricted distribution of the non-classical HLA class I molecule HLA-G, the low polymorphism in the coding region, the fact that HLA-G primary transcript is alternatively spliced in seven isoforms, and the inhibitory action on immune cells, constitute four hallmarks of HLA-G, which set it apart from other HLA class I molecules. Although the HLA-G locus is of low polymorphism, variants in both its promoter and 3’ un-translated region (UTR) regulate its expression.
In healthy conditions, a basal level of HLA-G gene transcription is observed in most cells and tissues; however, translation into HLA-G protein is restricted to trophoblasts in the placenta where it participates in the tolerance at the fetal-maternal interface. HLA-G is also expressed by thymic epitelial, cornea, mesenchymal stem cells (MSCs), nail matrix, pancreatic beta cells, erythroid and endothelial precursors.
HLA-G can be neo-expressed in adult tissues in pathological conditions, and its expression has been documented autoimmune disorders, viral infections, and especially cancer. In the latter settings de novo HLA-G expression is associated with the capability of solid tumor cells to evade the immune control.
In the last decade it has become evident that HLA-G expression on T cells and antigen-presenting cells confers them tolerogenic properties. This Research Topic will focus on i) summarizing clinical and immunological evidence on the significance of HLA-G expression for beneficial tolerance or detrimental immune escape, ii) gathering new insights into the mechanisms governing the expression of HLA-G in healthy and pathological conditions, and iii) examining the mechanisms underlying HLA-G mediated tolerance, in order to broader the comprehension of the tolerogenic role mediated by HLA-G and to ultimately advance the definition of novel therapeutic strategies to promote or inhibit HLA-G-mediated tolerance.
In healthy conditions, a basal level of HLA-G gene transcription is observed in most cells and tissues; however, translation into HLA-G protein is restricted to trophoblasts in the placenta where it participates in the tolerance at the fetal-maternal interface. HLA-G is also expressed by thymic epitelial, cornea, mesenchymal stem cells (MSCs), nail matrix, pancreatic beta cells, erythroid and endothelial precursors.
HLA-G can be neo-expressed in adult tissues in pathological conditions, and its expression has been documented autoimmune disorders, viral infections, and especially cancer. In the latter settings de novo HLA-G expression is associated with the capability of solid tumor cells to evade the immune control.
In the last decade it has become evident that HLA-G expression on T cells and antigen-presenting cells confers them tolerogenic properties. This Research Topic will focus on i) summarizing clinical and immunological evidence on the significance of HLA-G expression for beneficial tolerance or detrimental immune escape, ii) gathering new insights into the mechanisms governing the expression of HLA-G in healthy and pathological conditions, and iii) examining the mechanisms underlying HLA-G mediated tolerance, in order to broader the comprehension of the tolerogenic role mediated by HLA-G and to ultimately advance the definition of novel therapeutic strategies to promote or inhibit HLA-G-mediated tolerance.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
